Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
LBPH Stock Price Chart Interactive Chart >
LBPH Price/Volume Stats
| Current price | $5.03 | 52-week high | $18.50 |
| Prev. close | $4.74 | 52-week low | $3.90 |
| Day low | $4.58 | Volume | 10,100 |
| Day high | $5.15 | Avg. volume | 20,821 |
| 50-day MA | $5.01 | Dividend yield | N/A |
| 200-day MA | $6.30 | Market Cap | 68.34M |
Longboard Pharmaceuticals, Inc., (LBPH) Company Bio
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Latest LBPH News From Around the Web
Below are the latest news stories about Longboard Pharmaceuticals Inc that investors may wish to consider to help them evaluate LBPH as an investment opportunity.
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual ConferenceSAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at the H.C. Wainwright BioConnect Virtual Conference. The presentation webcast will be available beginning Monday, January 10, 2022, at 7:00 AM ET. To access a webcast of the presentation, please visit the “Even |
Longboard Pharmaceuticals (NASDAQ:LBPH) Cut to Hold at Zacks Investment ResearchZacks Investment Research lowered shares of Longboard Pharmaceuticals (NASDAQ:LBPH) from a buy rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. According to Zacks, Longboard Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel, transformative medicines for neurological diseases. Longboard Pharmaceuticals Inc. is based in SAN [] |
We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Longboard Pharmaceuticals (NASDAQ:LBPH) Lifted to Buy at Zacks Investment ResearchLongboard Pharmaceuticals (NASDAQ:LBPH) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Tuesday, Zacks.com reports. The firm presently has a $6.50 target price on the stock. Zacks Investment Researchs price objective points to a potential upside of 23.81% from the companys previous close. [] The post Longboard Pharmaceuticals (NASDAQ:LBPH) Lifted to Buy at Zacks Investment Research appeared first on ETF Daily News . |
Longboard Pharmaceuticals, Inc. (LBPH) Could Find Support Soon, Here's Why You Should Buy the Stock NowLongboard Pharmaceuticals, Inc. (LBPH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
LBPH Price Returns
| 1-mo | 3.07% |
| 3-mo | 5.45% |
| 6-mo | -14.75% |
| 1-year | -40.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 3.07% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...